Hormonal contraception and obesity

Katharine Simmons, Alison Edelman

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The rising rate of overweight and obesity is a public health crisis in the United States and increasingly around the globe. Rates of contraceptive use are similar among women of all weights, but because contraceptive development studies historically excluded women over 130% of ideal body weight, patients and providers have a gap in understanding of contraceptive efficacy for obese and overweight women. Because of a range of drug metabolism alterations in obesity, there is biologic plausibility for changes in hormonal contraception effectiveness in obese women. However, these pharmacokinetic changes are not linearly related to body mass index or weight, and it is unknown what degree of obesity begins to affect pharmacokinetic or pharmacodynamics processes. Overall, most studies of higher quality do not demonstrate a difference in oral contraceptive pill effectiveness in obese compared with non-obese women. However, data are scant for women in the highest categories of obesity, and differences by progestin type are incompletely understood. Effectiveness of most non-oral contraceptives does not seem to be compromised in obesity. Exceptions to this include the combined hormonal patch and oral levonorgestrel emergency contraception, which may have lower rates of effectiveness in obese women. The purpose of this review is to summarize evidence on contraceptive use in women with obesity, including differences in steroid hormone metabolism, contraceptive effectiveness, and safety, compared with women of normal weight or body mass index using the same methods.

Original languageEnglish (US)
Pages (from-to)1282-1288
Number of pages7
JournalFertility and Sterility
Volume106
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Contraception
Obesity
Contraceptive Agents
Weights and Measures
Body Mass Index
Pharmacokinetics
Postcoital Contraception
Ideal Body Weight
Levonorgestrel
Progestins
Oral Contraceptives
Public Health
Steroids
Hormones
Safety
Pharmaceutical Preparations

Keywords

  • Contraception
  • effectiveness
  • obesity
  • pharmacokinetics
  • safety

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Hormonal contraception and obesity. / Simmons, Katharine; Edelman, Alison.

In: Fertility and Sterility, Vol. 106, No. 6, 01.11.2016, p. 1282-1288.

Research output: Contribution to journalReview article

Simmons, Katharine ; Edelman, Alison. / Hormonal contraception and obesity. In: Fertility and Sterility. 2016 ; Vol. 106, No. 6. pp. 1282-1288.
@article{ed7084ddf4b54202a7517217010d97d8,
title = "Hormonal contraception and obesity",
abstract = "The rising rate of overweight and obesity is a public health crisis in the United States and increasingly around the globe. Rates of contraceptive use are similar among women of all weights, but because contraceptive development studies historically excluded women over 130{\%} of ideal body weight, patients and providers have a gap in understanding of contraceptive efficacy for obese and overweight women. Because of a range of drug metabolism alterations in obesity, there is biologic plausibility for changes in hormonal contraception effectiveness in obese women. However, these pharmacokinetic changes are not linearly related to body mass index or weight, and it is unknown what degree of obesity begins to affect pharmacokinetic or pharmacodynamics processes. Overall, most studies of higher quality do not demonstrate a difference in oral contraceptive pill effectiveness in obese compared with non-obese women. However, data are scant for women in the highest categories of obesity, and differences by progestin type are incompletely understood. Effectiveness of most non-oral contraceptives does not seem to be compromised in obesity. Exceptions to this include the combined hormonal patch and oral levonorgestrel emergency contraception, which may have lower rates of effectiveness in obese women. The purpose of this review is to summarize evidence on contraceptive use in women with obesity, including differences in steroid hormone metabolism, contraceptive effectiveness, and safety, compared with women of normal weight or body mass index using the same methods.",
keywords = "Contraception, effectiveness, obesity, pharmacokinetics, safety",
author = "Katharine Simmons and Alison Edelman",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.fertnstert.2016.07.1094",
language = "English (US)",
volume = "106",
pages = "1282--1288",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Hormonal contraception and obesity

AU - Simmons, Katharine

AU - Edelman, Alison

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The rising rate of overweight and obesity is a public health crisis in the United States and increasingly around the globe. Rates of contraceptive use are similar among women of all weights, but because contraceptive development studies historically excluded women over 130% of ideal body weight, patients and providers have a gap in understanding of contraceptive efficacy for obese and overweight women. Because of a range of drug metabolism alterations in obesity, there is biologic plausibility for changes in hormonal contraception effectiveness in obese women. However, these pharmacokinetic changes are not linearly related to body mass index or weight, and it is unknown what degree of obesity begins to affect pharmacokinetic or pharmacodynamics processes. Overall, most studies of higher quality do not demonstrate a difference in oral contraceptive pill effectiveness in obese compared with non-obese women. However, data are scant for women in the highest categories of obesity, and differences by progestin type are incompletely understood. Effectiveness of most non-oral contraceptives does not seem to be compromised in obesity. Exceptions to this include the combined hormonal patch and oral levonorgestrel emergency contraception, which may have lower rates of effectiveness in obese women. The purpose of this review is to summarize evidence on contraceptive use in women with obesity, including differences in steroid hormone metabolism, contraceptive effectiveness, and safety, compared with women of normal weight or body mass index using the same methods.

AB - The rising rate of overweight and obesity is a public health crisis in the United States and increasingly around the globe. Rates of contraceptive use are similar among women of all weights, but because contraceptive development studies historically excluded women over 130% of ideal body weight, patients and providers have a gap in understanding of contraceptive efficacy for obese and overweight women. Because of a range of drug metabolism alterations in obesity, there is biologic plausibility for changes in hormonal contraception effectiveness in obese women. However, these pharmacokinetic changes are not linearly related to body mass index or weight, and it is unknown what degree of obesity begins to affect pharmacokinetic or pharmacodynamics processes. Overall, most studies of higher quality do not demonstrate a difference in oral contraceptive pill effectiveness in obese compared with non-obese women. However, data are scant for women in the highest categories of obesity, and differences by progestin type are incompletely understood. Effectiveness of most non-oral contraceptives does not seem to be compromised in obesity. Exceptions to this include the combined hormonal patch and oral levonorgestrel emergency contraception, which may have lower rates of effectiveness in obese women. The purpose of this review is to summarize evidence on contraceptive use in women with obesity, including differences in steroid hormone metabolism, contraceptive effectiveness, and safety, compared with women of normal weight or body mass index using the same methods.

KW - Contraception

KW - effectiveness

KW - obesity

KW - pharmacokinetics

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84994036112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994036112&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2016.07.1094

DO - 10.1016/j.fertnstert.2016.07.1094

M3 - Review article

C2 - 27565257

AN - SCOPUS:84994036112

VL - 106

SP - 1282

EP - 1288

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -